We should not distinguish between symptomatic and disease‐modifying treatments in Alzheimer's disease drug development-Reference-Cited by-同舟云学术

We should not distinguish between symptomatic and disease‐modifying treatments in Alzheimer's disease drug development

Published:2007-12-21 Issue:1S1 Volume:4 Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Doody Rachelle S.¹

Affiliation:

1. Baylor College of MedicineHoustonTXUSA

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Clinical Neurology,Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.jalz.2007.10.010

Reference21 articles.

1. Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type

2. Donepezil Improves Cognition and Global Function in Alzheimer DiseaseA 15-Week, Double-blind, Placebo-Controlled Study

3. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

4. Observations and suggestions on antidementia drug development;Leber P.;Alzheimer Dis Assoc Disord,1996

5. A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters;Epilepsia;2022-08-17

2. Old Age Dementias: Factors Associated with Dementia Progression Rate. Part 2;Psikhiatriya;2020-12-15

3. The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments;Neuropharmacology;2020-05

4. US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development;Clinical and Translational Science;2020-03-03

5. Labeling of Disease-Modifying Therapies for Neurodegenerative Disorders;Frontiers in Medicine;2019-10-17